ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence
CPT4 code
Name of the Procedure:
ASXL1 (Additional Sex Combs Like 1, Transcriptional Regulator) Full Gene Sequence Analysis
Summary
ASXL1 gene analysis is a genetic test that examines the entire sequence of the ASXL1 gene to identify mutations or abnormalities. This test is significant for diagnosing and managing blood disorders such as myelodysplastic syndrome, myeloproliferative neoplasms, and chronic myelomonocytic leukemia.
Purpose
This procedure helps identify mutations in the ASXL1 gene that are often associated with certain blood disorders. The goal is to enable accurate diagnosis, guide treatment decisions, and provide a prognosis for conditions such as myelodysplastic syndrome, myeloproliferative neoplasms, and chronic myelomonocytic leukemia.
Indications
- Unexplained anemia, leukopenia, or thrombocytopenia
- Suspected myelodysplastic syndrome, myeloproliferative neoplasms, or chronic myelomonocytic leukemia
- Patients with a family history of these conditions
- Abnormal blood counts or bone marrow findings that cannot be explained by other causes
Preparation
- No specific fasting or dietary restrictions are typically required.
- Patients may need to provide a blood sample or bone marrow aspirate.
- The patient’s healthcare provider may ask for a complete medical history and recent lab results.
Procedure Description
- Sample Collection: A blood sample is drawn from a vein, or a bone marrow aspirate is obtained under local anesthesia.
- DNA Extraction: The DNA is extracted from the collected sample in a laboratory.
- Sequencing: The ASXL1 gene is sequenced using next-generation sequencing technology.
- Analysis: Bioinformatics tools analyze the sequence data to identify mutations or abnormalities.
Duration
The sample collection process typically takes about 20-30 minutes. The entire process, including sequencing and analysis, may take several days to a few weeks, depending on the laboratory.
Setting
The sample collection is usually performed in a hospital or outpatient clinic. The sequencing and analysis occur in a specialized laboratory.
Personnel
- Phlebotomist or nurse for sample collection
- Laboratory technicians and geneticists for DNA extraction and sequencing
- Hematologists or oncologists for interpreting the results
Risks and Complications
- Minor discomfort or bruising at the blood draw site
- Rare risk of infection or bleeding at the bone marrow aspiration site
- Possibility of inconclusive results necessitating further testing
Benefits
The primary benefit is the accurate diagnosis and better understanding of specific blood disorders, which can lead to more targeted and effective treatments. Results can provide information on prognosis and guide treatment decisions.
Recovery
- For blood draws, minimal recovery is needed; patients can resume normal activities immediately.
- After a bone marrow aspiration, patients might experience mild discomfort, which can be managed with over-the-counter pain medications.
Alternatives
- Other genetic tests or panels that examine multiple genes involved in myelodysplastic syndromes and leukemias.
- Cytogenetic analysis and flow cytometry.
- The pros of ASXL1 gene analysis include its specificity and detailed information, but it may be more costly and time-consuming compared to other methods.
Patient Experience
- During the blood draw, patients may feel a quick pinch.
- Bone marrow aspiration may cause brief, sharp pain or pressure.
- Post-procedure pain is generally mild and manageable with simple pain relievers.
- Patients can discuss with their physician any concerns or the need for additional support or pain management options.